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This is the second of two articles in the October 
2005 issue on ways to create practical markets for 
vaccines.
T
hinking of ways to create 
practical markets for vaccines 
poses some interesting 
challenges, particularly in the context 
of introducing new and underutilized 
vaccines. In a complex, ever-changing 
world, making vaccines, whether they 
are new or old, available to children 
and families who need them most 
should be a top priority [1]. Models 
for creating markets have been 
recently developed that might beneﬁ  t 
from the experience gained from the 
regional and national immunization 
approaches used in the Americas. From 
the perspective of the Pan American 
Health Organization (PAHO), 
strategies to optimize the market and, 
ultimately, the use of vaccines include 
three important, overriding guiding 
principles: access, accelerated regional 
disease control, and the development 
of a public-health infrastructure.
Access Is Essential
Access to preventive and other 
health services covers several factors, 
including access to health units and 
hospitals, trained staff providing quality 
services, cost-effective technologies, 
the best use of available technologies, 
and information to improve the 
community’s knowledge base and best 
practices.
Inherently, improved access also 
addresses issues of equity. Equity is 
a critical cross-cutting concept that 
drives much of the work of PAHO 
and member countries. For vaccines, 
the challenge has always been, and 
will continue to be, to ensure that all 
communities beneﬁ  t from the potential 
impact of these technologies [2].
The Example of Rubella
The initiative to eliminate rubella 
and congenital rubella syndrome in 
the Americas serves as an example of 
PAHO’s member countries seizing 
the opportunity to ensure access, 
while promoting the ultimate goal of 
disease control (virtual elimination 
of a disease), and the improvement 
of the public-health infrastructure 
[3]. These efforts help ensure that 
all families receive the beneﬁ  t 
of vaccine technology because 
disease elimination requires that all 
communities be reached, regardless 
of ethnic background, religion, or 
income. Although the rubella vaccine 
was only recently introduced in many 
countries of the Americas, many of 
them simultaneously accelerated 
the rubella disease control strategies 
by strengthening surveillance 
and conducting mass vaccination 
campaigns to rapidly reduce the pool 
of rubella-susceptible individuals in the 
community. Such efforts eventually led 
to the adoption of a regional rubella-
elimination initiative in the Americas 
by the year 2010 [4].
Targeting High-Risk Districts
In the Americas, targeting high-
risk districts with low immunization 
coverage for special attention also 
promotes improved access and 
accelerated disease control. Efforts to 
strengthen leadership, management, 
and supervision of program activities 
have been essential for the success of 
this strategy. Districts that have less than 
95% coverage are targeted for special 
training, outreach, and follow-up. This 
targeting helps ensure that even in 
middle-income countries the substantial 
disparities that exist in health are 
addressed. To that end, PAHO’s 
member countries have conducted 
the annual Vaccination Week in the 
Americas, during which all countries 
attempt to reach and vaccinate 
marginalized, poor populations [5].
Global Approaches to Vaccination
In the context of access and equity, 
there is concern about global 
approaches to support only countries 
with average annual per capita income 
of less than $1,000, such as the 
approach taken by the Global Alliance 
for Vaccines and Immunization, thus 
limiting the scope of work and beneﬁ  ts 
that impoverished children and 
families could otherwise receive in the 
Americas. Currently, only six countries 
are eligible to receive support from 
the Global Alliance for Vaccines and 
Immunization: Bolivia, Cuba, Guyana, 
Haiti, Honduras, and Nicaragua—
representing only 7% of the population 
of the Caribbean and Latin America. 
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Public-sector capacity 
development creates 
regional independence.
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However, 11% of people in the 
Caribbean and Latin America live 
below the international poverty line 
($365 annual per capita income) [6]. 
In addition, huge discrepancies exist 
within countries, and these countries 
urgently need extra resources to ensure 
access of vaccines to marginalized 
populations. 
Disease Control in the Americas
In the Americas, efforts to control 
disease over the last 20 years have led to 
signiﬁ  cant improvements in the public-
health infrastructure, particularly in 
the area of program management, 
surveillance, and public-health 
laboratories. In some countries, such 
as Brazil, the development of public-
sector capacity for vaccine production 
was also a top priority. Such public-
sector capacity development creates 
regional independence, competition to 
reduce vaccine prices among private-
sector producers, and dependable 
supply chains that are sustained 
and that contribute to intercountry 
cooperation [7]. Currently, Brazil 
produces a yellow fever vaccine that 
has been used in (and in some cases 
donated to) neighboring countries 
suffering from deadly yellow fever 
outbreaks, for example, the yellow fever 
outbreak in Colombia in 2004.
Future Approaches to Practical 
Markets for Vaccines 
Future approaches that attempt to 
enhance practical markets for vaccines 
and that enhance the introduction 
of new and underutilized vaccines 
should consider prioritizing the 
following: access and equity for as 
much of the population as is possible, 
well-implemented accelerated disease-
control and prevention strategies, 
and development of a public-health 
infrastructure.
The general approach also requires 
high-level political commitment, 
adequate attention to management, 
supervision, and logistics, and sound 
technical strategies. The opportunity 
to address widespread disparities 
in health that exist in low- and low-
middle-income countries that otherwise 
do not beneﬁ  t from Global Alliance 
for Vaccines and Immunization’s 
marketing approaches will be a huge 
challenge for the future. PAHO will 
continue to make the support of 
immunization to member countries 
a priority.  
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